Breaking Finance News

STRATEC Biomedical (ETR:SBS) stock price target increased to 47.00EUR, issued a ratings update today by HSBC

Just yesterday STRATEC Biomedical (ETR:SBS) traded -0.92% lower at 42.42EUR. STRATEC Biomedical’s 50-day moving average is 9.53EUR and its 200-day moving average is 8.91EUR. The last stock price is up -3.48% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the same time period. 773,048 shares of SBS traded hands, down from an average trading volume of 1,707,990

In a report released on Saturday November 26, 2016 HSBC increased the stock price target of STRATEC Biomedical (ETR:SBS) to 47.00EUR reporting a potential upside of 0.11%.

Performance Chart

STRATEC Biomedical (ETR:SBS)

With a total market value of 0 EUR, STRATEC Biomedical has P/E ratio of 8.25 with a 52 week low of 3.98EUR and a 52 week high of 10.55EUR .

In addition to HSBC reporting its stock price target, a total of 3 analysts have released a research note on STRATEC Biomedical. The 12-month price target is 28.48EUR with zero brokerages rating the company a strong buy, zero brokerages rating the company a buy, zero equity analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the company a sell.

More About STRATEC Biomedical (ETR:SBS)

STRATEC Biomedical AG (STRATEC) is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics. STRATEC's partners market Company's products to pharmaceutical laboratories, blood banks and research institutes throughout the world. STRATEC Group operats through its four consolidated subsidiaries in Switzerland, the United Kingdom, Germany as well as the United States, comprising STRATEC Biomedical Switzerland AG, STRATEC Biomedical UK, Ltd, STRATEC Molecular GmbH and STRATEC Biomedical USA, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *